SAN
RAFAEL, Calif., Jan. 3, 2024
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today
announced that Alexander Hardy,
President and Chief Executive Officer of BioMarin, will present at
the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT /
1:30 pm ET, in San Francisco, California.
An audio webcast of the presentations will be available live.
You can access the webcasts at: https://investors.biomarin.com/. An
archived version of the remarks will also be available through the
Company's website for a limited time following the conference.
About BioMarin
Founded in 1997,
BioMarin is a global biotechnology Company
dedicated to transforming lives through genetic discovery. The
Company develops and commercializes targeted therapies that address
the root cause of the genetic conditions. BioMarin's
unparalleled research and development capabilities have
resulted in eight transformational commercial therapies for
patients with rare genetic disorders. The Company's distinctive
approach to drug discovery has produced a diverse pipeline of
commercial, clinical, and pre-clinical candidates that address a
significant unmet medical need, have well-understood biology, and
provide an opportunity to be first-to-market or offer a substantial
benefit over existing treatment options. For additional
information, please
visit www.biomarin.com.
Contacts:
|
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
|
Media
Marni Kottle
BioMarin Pharmaceutical Inc.
(650) 374-2803
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-on-monday-january-8-at-1030-am-pt--130-pm-et-in-san-francisco-ca-302025143.html
SOURCE BioMarin Pharmaceutical Inc.